Under the stewardship of The Economist editors, this inaugural event on cell and gene therapies takes place on April 24th – 25th 2023 in Brussels, Belgium. The summit convenes stakeholders from a range of industries. These important decision-makers will advance the conversation on expediting transformative products to market.
Cell and gene therapies are redefining the treatment of many diseases, giving hope to patients who previously had no therapeutic options. These treatments can be transformative in the battle against cancer, genetic disorders and rare diseases. In the UK, NICE expects to review 30 new cell and gene therapy products by 2023, with the FDA in the US predicting between 15 and 20 new products will be on the market by 2025. Attendees will learn how healthcare systems and policies need to evolve before these therapies can become mainstream.
Through a series of interactive sessions, industry stakeholders will debate the challenges of bringing these therapies to market—including manufacturing, real-world data collection and their commercial sustainability. The conference programme examines the potential for a healthcare paradigm shift, as public opinion and patient experience evolve.
Here are the top three reasons why you should attend Cell and Gene Therapy Summit:
- Commercial and policy-focused.This event is distinct from others as it explores industry systems—rather than just science. Pharmaceutical companies will gain a deeper understanding of reimbursement and policy.
- A timely event.NICE expects to review 30 new cell and gene therapy products in the next year, with the FDA predicting there could be between15 and 20 new products on the market by 2025. Around next spring, some of these will have moved through approval to distributions, proving many practical
takeaways for attendees. - Simplify the chatter.Under the stewardship of The Economist editors, the inaugural event on cell and gene therapies convenes important decision-makers. Attendees will advance the conversation on how to expedite transformative products to market.
Well, if you’re still giving it a second thought, tickets are selling fast. Go grab yours now, before we run out!
Speakers include:
- Henny Braund, chief executive, Anthony Nolan
- Steven Pearson, chief executive, ICER
- Natasha Loder, health policy editor, The Economist
- Hugues Malonne, director general pre-authorisation, Belgian Federal Agency for Medicines & Health Products
- Declan Noone, president, European Haemophilia Consortium
- Dr Patrick Celis, scientific lead, Committee for Advanced Therapies (CAT), ATMP Office, European Medicines Agency
- Professor Claire Booth, professor of gene therapy and paediatric immunology, UCL GOSH Institute of Child Health
- Len Valentino, president and chief executive, National Hemophilia Foundation
- Alexander Natz, secretary-general, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
- Michele Salter, chair, Sickle Cell Society
- Mark Battaglini, chief strategy officer, Alliance for Regenerative Medicine (ARM)
- Dr Androulla Eleftheriou, executive director, Thalassaemia International Federation
- Lutz Bonacker, senior vice-president and general manager Europe, CSL Behring
- Dr Matthew Brown, medical director, Group Clinical, Bupa
- Professor Flora Peyvandi, professor of Internal Medicine, University of Milan, director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico
- Ondřej Knotek, member of the European Parliament
- Sirpa Pietikäinen, member of European Parliament for Finland
- Ana Hidalgo-Simon, associate professor, Leiden University Medical Centre
- Sander van Deventer, chief executive, VectorY and operating partner, Forbion
- Jennifer Lee, therapy area market access leader EMEA, Janssen
- Marcus Guardian, chief operating officer, EUnetHTA
- Julie Lekstrom Himes, vice-president and head, clinical science, rare genetics and hematology, Takeda Pharmaceutical Company
- Joseph ‘Mike’ McCune, head, HIV frontiers, global health accelerator, Bill & Melinda Gates Foundation
- Petra Reinke, founding director, Berlin Center for Advanced Therapies, The Charite Universitätsmedizin Berlin
- Miguel Forte, president-elect, International Society for Cell & Gene Therapies
- Rebecca Middleton, Chief executive, Hereditary Brain Aneurysm Support
- Professor Wolfgang Miesbach, treasurer, chair – gene therapy working group, EAHAD
- Elisa Petris, partner, Syncona Limited
- Dr Christos Tsagkaris, medical doctor, member, European Health Parliament, trustee board member, Institute of Cancer and Crisis
- Lung-I Cheng, vice president cell and gene therapy commercial solutions, AmerisourceBergen
- Boro Dropulić, co-founder and executive director, Caring Cross
- Jo Pisani, trustee of Beacon, and chair of collective’s patient advocacy summit, Cell & Gene Collective
- Marco Boorsma, general partner, Forbion
- Dmitry ‘Dima’ Kuzmin, managing partner, 4BIO
- William Cole, life sciences partnership manager, Kidney Research UK
- Ann Hunter van Kirk, senior equity research analyst biopharmaceuticals, Bloomberg
- Panos Kefalas, director of access strategy, Cell & Gene Therapy Catapult
- Jen Adair, associate professor, clinical research division, Fleischauer Family Endowed Chair in Gene Therapy Translation, Fred Hutch
- Joep Muijrers,general partner, Gilde Healthcare
- Victor Maertens, government affairs manager, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Discover the potential for a healthcare paradigm shift with our inaugural event. Examine how healthcare systems, pricing and policies need to evolve before essential cell and gene therapies can become mainstream.
